PublicationsWennerås C, Hagberg L, Andersson R, Hynsjö L, Lindahl A, Okroj M, Blom A, Johansson P, Andreasson B, Gottfries J, Wold ADistinct inflammatory mediator patterns characterize infectious and sterile systemic inflammation in febrile neutropenic hematology patientsPLoS One. 2014; 9(3): e92319. Published online Mar 18, 2014

Holly L. Geyer,1 Robyn M. Emanuel,Amylou C. Dueck, Jean-JacquesKiladjian, Zhijian Xiao,Stefanie Slot, Sonja Zweegman, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Konstanze Döh-ner,Claire N. Harrison, Deepti Radia, Pablo Muxi, Carlos Besses,Francisco Cervantes, Peter L. Johansson, Bjorn Andreasson, AlessandroRambaldi, Tiziano Barbui, Alessandro M. Vannucchi, Francesco Passamonti, Jan Samuelsson, Gunnar Birgegard, and Ruben A. MesaDistinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patientsBlood. 2014;123:3803-10.

Johan Liwing, Katarina Uttervall, Johan Lund, Anders Aldrin, Cecilie Blimark, Kristina Carlson, Jon Enestig, Max Flogegård, Karin Forsberg, Astrid Gruber, Helene Haglöf Kviele, Peter Johansson, Birgitta Lauri, Ulf-Henrik Mellqvist, Agneta Swedin, Magnus Svensson, Per Näsman, Evren Alici, Gösta Gahrton, Johan Aschan and Hareth Nahi. Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal populationBritish Journal of Hematology 2014;164:684-693

Abelsson J, Andreasson B, Samuelsson J, Hultcrantc M, Ejerbladh E, Johansson B, Emanul R, Mesa R, Johansson P. Patients with polycythemia vera have the worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasmsLeuk Lymphoma. 2013 Oct;54:2226-30]

Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, Te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs J Clin Oncol. 2012;30:4098-103

Bonicelli G, Abdulkarim K, Mounier M, Johansson P, Rossi C, Jooste V, Andreasson B, Maynadié M, Girodon F. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients.Br J Haematol. 2013;160:251-4]

Lindgren Marie, Pettersson Helna, Westin Johan, Lindh Magnus, Johansson P, Andreasson Björn. Influence of interferon-α treatment outcome in polycythemia vera and essential thrombocythemia by genetic polymorphism in IL28B. Journal of Hematological Malignancies 2012;2:18-25

Johansson M, Johansson P. Elderly with multiple diseases often in contact with health services should be admit-ted right away. Study of 40 patients in the NU-healthcare. Läkartidningen 2012;109:1022-3.

J Abelsson, M Merup, G Birgegård, O WeisBjerrum, L Brinch, M Brune, P Johansson, M Kauppil, S Lenhoff,M Liljeholm, C Malm, K Remes, L Vindelöv and B Andréasson for the Nordic MPD Study GroupThe outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries.Bone Marrow Transplantation 2012:47:380-386

Johansson P, Mesa R, Scherber R, Abelsson J, Samuelsson J, Birgegård G, Andréasson B.Leuk Lymphoma. 2012;53:441-4.

Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms

Scherber R. Dueck A, Johansson P, Barbui T, Barosi G, Vannucchi A, Passamonti F, Andreasson B, Ferarri M, Rambadli A, Samuelsson J, Birgegård G, Tefferi A, Harrison C, Radia D, Mesa R.

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial In 402 Patients. Blood. 2011;118:401-8.

Abdulkarim K, Ridell R, Johansson P, Kutti J, Safai-Kutti S, Andreasson BThe impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera

European Journal of Haematology 2011;86:148-155

Andreasson B, Johansson P, Samuelsson J Essentiell trombocytosis- a criteria diagnosis. Important to differentiate from reactive/secondary thrombocytosis. Läkartidningen 2009:106:110-113

Johansson P, Andreasson B, Samuelsson J. Polycythemia vera-focus on the Hb value. Future treatment can maybe result in disease remission. Läkartidningen 2009:106:104-109

Abdulkarim K, Girodon F, Johansson P, Maynadie M, Kutti J, Carli P, Bovet E, Andreasson B. AML transformation in 56 patients with Ph- MPD in two well defined populations. European Journal of Haematology. 2008;82:106-111

Chantzichristos D, Andreasson B, Johansson P. One hour pamidronate infusion, safe and tolerable in patients with myeloma. Therapeutic and clinical risk management 2008;4:1371-1374

Ricksten A, Palmqvist L, Johansson P, Andreasson B. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica 2008;93:1260-1261

Schwemmers S, Will B, Waller C, Abdulkarim K, Johansson P, Andreasson B, Pahl H. JAK2V617F –negative ET patients do not display constitutively active JAK/STAT signaling. Experimental Hematology 2007;35:1695-703

Ahlqvist-Rastad J, Albertsson M, Bergh J, Birgegård G, Johansson P, Jonsson B, Kjellen E, Påhlman S, Zackrisson B, Österborg A.Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations Medical Oncology 2007;24:267-272

Johansson P, Andréasson B. Hydroxyurea therapy increases plasma erythropoietin in patients with essential thrombocythaemia or polycythaemia vera. Clinical and Laboratory Haematology 2006;28:233-236

Johansson P Epidemiology of the myeloproliferative disorders PV and ET. Seminars in Thrombosis and Hemostasis 2006;32:171-173

Goerttler P, Steimle C, März E, Johansson P, Andréasson B, Griesshammer , Gisslinger H, Heimpel H, Pahl H. The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood 2005;106:2862-2864

Goerttler P, März E, Johansson P, Andréasson B, Kutti J, Moliterno A, Marchioloi R, Spivak J, Pahl H. Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-MPL protein expression and PRV-1 mRNA levels.Haematologica 2005;90:851-853

Johansson P, Safai-Kutti S, Kutti JAn elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis. a study of patients with polycythaemia vera and apparent polycthaemia.British Journal of Haematology 2005;129:701-705

Johansson P, Ricksten A, Wasslavik C, Johansson B, Andréasson B.The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.Haematologica 2004;89:1264-1266

Cherif H, Björkholm M, Engervall P, Johansson P, Ljungman P, Hast R, Kalin M.A prospective , randomized study comparing cefepim and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.Scand J Infect Dis 2004;36:593-600

Johansson P, Kutti J, Andréasson B, Safai-Kutti S, Vilén L and Wedel H.Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99.Journal of Internal Medicine 2004;256:161-165

Palmqvist L, Goerttler P, Wasslavik C, Johansson P, Andreasson B, Safai-Kutti S, Kutti J, Pahl H and Ricksten AMethod comparision of PRV-1 mRNA quantification in whole blood leukocytes and purified granulocytesClinical Chemistry 2004;50:644-647

Johansson P, Brudin G, Nilsson B and Andréasson BOxygen affinity is decreased in patients with polycythaemia vera and essential thrombocythaemiaScandinavian Journal of Clinical and Laboratory Investigation 2004;64:71-76

Johansson P, Ricksten A, Wennström L, Palmqvist L, Kutti J and Andréasson BIncreased risk for vascular complications in PRV-1 positive patients with essential thrombocythaemiaBritish Journal of Haematology 2003;123:513-516

Johansson P, Andreasson B, Safai-Kutti S, Wennström L, Palmqvist L , Ricksten A, Lindstedt G and Kutti JThe presence of a significant association between elevated PRV-1 mRNA expression and low plasma erythropoietin concentration in essential thrombocythaemiaEuropean Journal of Haematology 2003;70:358-362

Johansson P, Safai-Kutti S, Lindstedt G, Suurküla M, Kutti JThe red cell mass, spleen size and plasma erythropoietin in polycythaemia vera and apparent polycythemia. Acta Haematologica 2002;108:1-7

Johansson P, Andreasson B, Safai-Kutti S, Rhedin C, Vilén L, Kutti JOn the diagnosis of polycythaemia vera as assessed in the health and medical care in the Västra Götaland region, Sweden.Journal of Internal Medicine 2002;251:348-354

Johansson P, Stockelberg D, Ekman T, Ridell BBilateral trephine biopsy in the diagnosis of lymphoma. Is unilateral biopsy enough?Haematologica 1999;84(suppl 1):650

Lindblad R, Rödjer S, Adriansson M, Andreasson B, Backstrom B, Johansson P, Karlsson K, Rhedin C, Turesson IEmpiric monotherapy for febrile neutropenia-a randomized study comparing meropenem with ceftazidime.Scandinavian Journal of Infectious Diseases 1998;30(3):237-43Other publications

Kliniskt genomslag för JAK2-mutation. Onkologi i Sverige 2007;02

Medicinklinikens akutkompendium-Uddevalla Sjukhus (1998, 2002, 2005)

Profylax och terapiråd Tromboembolism Läkemedelskommitten i Nordvästra Götaland, 2006

Paroxysmal nattlig hemoglobinuri 2009 Socialstyrelsen /Ovanliga diagnoser

http://www.socialstyrelsen.se/ovanligadiagnoser/paroxysmalnattlighemoglobinuri

Internetmedicin om Myelofibros; http://www.internetmedicin.se/dyn_main.asp?page=4691

Internetmedicin om PNH: http://www.internetmedicin.se/page.aspx?id=5842

Internetmedicin om Polycytemia Vera: http://www.internetmedicin.se/page.aspx?id=3455